NFKB1 and neoplasm: It was demonstrated in vivo that a non-canonical NF-κB pathway inhibitor could produce tumor growth delay with 20 Gy ionizing radiation in an interferon-dependent manner using an immunocompetent mouse with subcutaneous tumors (Hou et al., 2018).